جستجوی مقالات مرتبط با کلیدواژه "بتامتازون" در نشریات گروه "پزشکی"

Atopic dermatitis is a common disease in infants and children which is chatacterized with pruritus and skin lesions and is known to be chronic and recurrent. Since the side effects caused by common treatments (topical corticosteroids) may cause a limitation to their long-term use, the need for alternative treatments is mandatory. Considering the anti-inflammatory effects, immune system, and sleep-regulating properties of melatonin, this study compared the effects of topical betamethasone alone with topical betamethasone combined with oral melatonin in the atopic treatment dermatitis.

This clinical trial was carried out on 50 patients with atopic dermatitis. Participants were randomly assigned to two treatment groups. The control group received betamethasone, and the intervention group, in addition to betamethasone, received 3 mg melatonin tablets for 12 weeks. The disease status of participants was also assessed using the Scoring Atopic Dermatitis (SCORAD) scale.

Both treatment groups showed significant changes in SCORAD score, affected area, disease intensity, and reported symptoms like insomnia and itching. So, the SCORAD index in the intervention and control groups decreased on average by 29.44 ± 14.09 and 33.56 ± 16.08, respectively, at the end of the treatment. But, no significant difference was observed between the two groups in these changes. Additionally, no specific treatment-related side effects also were reported during this study.

Although both treatment regimens resulted in significant improvement in the condition of atopic dermatitis, this study found no significant difference in the effectiveness of the two treatment regimens, suggesting the need for further investigation into alternative topical corticosteroid therapies to provide similar efficacy with reduced side effects.

Epidemic keratoconjunctivitis is a type of conjunctivitis caused by adenoviruses that can spread rapidly through direct and indirect contact. The aim of this study was to evaluate the therapeutic effects of povidone-iodine 0.4% and 0.2% in the improvement of the symptoms and signs of patients with epidemic keratoconjunctivitis.

This clinical trial study included 60 patients with a mean age of 27.8±8.4 years who met our inclusion criteria.The patients were randomly divided into three groups. The first group received povidone-iodine 0.4% and betamethasone 0.1% eye drops the second group received povidone-iodine 0.2% and betamethasone 0.1% eye drops and the third group received betamethasone 0.1% eye drop.  Follow-ups visits were on the first, fourth, seventh and tenth days after starting treatment. Parameters examined at each examination were hyperaemia, mucopurulent discharge, eyelid edema, hemorrhage, and subepithelial infiltration.

The results showed significant differences in the mucopurulent discharge among the treatment groups on the fourth day (P = 0.005) and also on the seventh day (P = 0.001) of the examination. There was no significant difference among the 3 groups in regard to sub-epithelial infiltration on the tenth day after treatment (P = 0.287).

Based on the results of this study, povidone-iodine was more effective than steroids alone in relieving some of the signs of EKC, such as mucopurulent discharge.

 Due to the existence of various issues and limitations associated with traditional buccal drug delivery systems such as the disability to consume food whilst using topical drugs in the mouth cavity, unpredictable drug release profile, undesirable taste, low patient adherence to therapy, and accelerated drug removal with saliva, these conventional methods are now rapidly becoming replaced with oral thin films as more precise and novel oral drug delivery platforms. The current study aims to discuss the design and characterization of betamethasone-loaded oral thin films with the aim of improved drug delivery in mouth cavity diseases.

 In this study, oral thin films with and without betamethasone were fabricated through the solvent casting method as a common, fast, and affordable technique prior to being evaluated for different physiochemical characteristics including weight, width, surface pH, disintegration period in vitro conditions, and swelling rates as well as drug release profiles at different intervals.

 Obtained oral films were demonstrated to possess adequate homogeneity, flexibility, and mechanical resistance. Accordingly, the average surface pH for films without and with betamethasone was equal to 6.75 and 6.66, respectively, which are in notable compatibility with the neutral pH of the oral cavity. Betamethasone-loaded films’ disintegration duration appeared to be superior to that of films without betamethasone and was in close correlation with their higher swelling rates. Further experiments revealed 25-30% drug release in the initial 20 minutes, followed by more than 90% betamethasone release in 360 minutes in a sustained manner.

 These results are indicative of betamethasone oral films’ satisfactory physiochemical properties and potential applicability as a sufficient oral drug delivery platform in mouth cavity diseases such as oral lichen planus or recurrent mouth sores. By sticking to the mouth mucosa, these films can significantly reduce drug removal with saliva and thus ameliorate sufficient delivery of therapeutic agents to specific mouth lesions. Moreover, they can alleviate some of the issues and limitations of traditional topical oral drug delivery and improve treatment or control of disease symptoms.

Sulfur mustard, Bis [2-chlorethyl] sulfide (HD), is one of the first chemical warfare agents to be used on a large scale. Anti inflammatory treatments might have the potential to prevent some aspects of the primary development of HD-induced lesions. The aim of the present study was to evaluate treatment effects of topically applied betamethasone (B) and diclofenac-Na (D) on the conjunctival epithelial lesions following HD exposure.

A total of 36 rabbits were used. Animals were randomly divided to three control groups: (1) normal (2) solution (3) HD and three experimental groups: (4) betamethasone (5) diclofenac-Na and (6) betamethasone-diclofenac-Na (BD). In each group six animals were examined. Right eye of all animals was selected for experiment. In the experimental groups betamethasone and diclofenac-Na were applied after using HD solution. Application of drugs was performed 3 times a day for 2 weeks. Slit-lamp examinations were performed before exposure and subsequently at days 1, 2, 5, 7, and 14 by professional ophthalmologists. Animals were sacrificed after two weeks with chloroform. The eyes were enucleated. Specimens of palpebra were obtained for histological examination.

There was not any significant difference between normal and solution groups. HD caused a significant decrease in goblet cells and cell infiltration in conjunctiva, injection and chemosis. All experimental groups were better than the HD group. Betamethasone in combination with diclofenac-Na was more effective than betamethasone and diclofenac-Na alone in decreasing eye injuries.

Combination of betamethasone and diclofenac-Na are potential candidates for the treatment of ocular lesions following HD exposure.